HLA-B 1502 for carbamazepine toxicity

Reduce the risk of severe medication-related adverse reactions with the HLA-B*1502 Test for Carbamazepine Toxicity at Lucid Medical Diagnostics in Hyderabad. This advanced molecular genetic test detects the HLA-B*1502 allele, which is strongly associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in individuals treated with carbamazepine. The test is recommended before initiating carbamazepine therapy, particularly in at-risk populations, to support safer and personalized treatment decisions. Using advanced molecular diagnostic technology and stringent quality standards, Lucid Medical Diagnostics delivers accurate, reliable, and timely results to enhance patient safety and clinical outcomes.

Home Sample Collection Available
Get Reports